Loading publications…
The last 5 uploaded publications
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe
Giancarlo Agnelli, Ulrich Hoffmann, Pierre Hainaut, Seán Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jiménez, Eva‐Maria Fronk, José Souza, Petra Laeis, Peter Bramlage, Bernd Brüggenjürgen, Pierre Lévy, Alexander T. Cohen (2025). Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe. , DOI: https://doi.org/10.1055/a-2497-4089.
Article76 days agoETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban
Marc Schindewolf, Bernd Brüggenjürgen, Cihan Ay, Pierre Hainaut, Ulrike Hoffmann, Seán Gaine, Michiel Coppens, Daniela Jimenez-Harrison, Patrick Lévy, Julio López Bastida, Éric Vicaut, Peter Bramlage, Giancarlo Agnelli, A. Cohen (2020). ETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban.
Article76 days agoETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries
Alexander T. Cohen, Ulrich Hoffmann, Pierre Hainaut, Seán Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jiménez, Bernd Brüggenjürgen, Pierre Lévy, Petra Laeis, Eva‐Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Marius Constantin Manu, Paul‐Egbert Reimitz, Peter Bramlage, Giancarlo Agnelli (2020). ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. , 82, DOI: https://doi.org/10.1016/j.ejim.2020.08.014.
Article76 days agoETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months
Marius Constantin Manu, Paul‐Egbert Reimitz, Peter Bramlage, Alexander T. Cohen, Giancarlo Agnelli, Ulrich Hoffmann, Pierre Hainaut, Seán Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jiménez, Bernd Brüggenjürgen, Pierre Lévy, Petra Laeis, Eva‐Maria Fronk, Wolfgang Zierhut, Thomas Malzer (2020). ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. , 196, DOI: https://doi.org/10.1016/j.thromres.2020.09.001.
Article76 days agoAssociation between index venous thromboembolism (VTE) event and 12-months outcomes for patients in routine clinical practice enrolledin the Edoxaban Treatment in routine cliNical prActice for patients with acute VTE in Europe (ETNA-VTE-Europe) registry
Michiel Coppens, Alexander T. Cohen, Cihan Ay, Pierre Hainaut, Ulrich Hoffmann, Seán Gaine, David Jiménez, Marc Schindewolf, Bernd Brüggenjürgen, Pierre Lévy, Julio López Bastida, Éric Vicaut, Peter Bramlage, Giancarlo Agnelli (2020). Association between index venous thromboembolism (VTE) event and 12-months outcomes for patients in routine clinical practice enrolledin the Edoxaban Treatment in routine cliNical prActice for patients with acute VTE in Europe (ETNA-VTE-Europe) registry. , DOI: https://doi.org/10.7892/boris.144861.
Article76 days ago